OncoMatch/Clinical Trials/NCT05653635

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

Is NCT05653635 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for glioblastoma.

Phase 2RecruitingCentre Paul StraussNCT05653635Data as of May 2026

ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Disease stage

Required: Stage IV (WHO)

Grade: IV (WHO)

Glioblastoma, World Health Organization (WHO) grade IV, histologically proven

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: radiation therapy — in previsional re-irradiated site or in the vicinity (5 to 7 cm)

Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify